Spruce Biosciences, Inc
SPRB
NASDAQ
Biotechnology
$52.64
USD
+2.87 (+5.77%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $136.98M
Volume 42.2K
Revenue
$0
TTM
-100.0%
YoY
Gross Margin
—
TTM
— YoY
Net Income
$-51.35M
TTM
-6.2%
YoY
Operating Cash Flow
$-42.62M
TTM
+17.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | -100.0% | -100.0% | -100.0% | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.1 | 3.2 | 7.0 | 4.4 | 4.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 2.7 | 8.2 | 11.1 | 12.0 | 16.5 |
Operating Income | -2.7 | -8.2 | -11.1 | -12.0 | -16.5 |
EBITDA | -2.7 | -8.2 | -11.1 | -11.7 | -15.9 |
Other Income / Expense | 0.5 | 0.0 | -3.5 | -0.1 | 0.6 |
Total Other Income / Expense | 0.6 | 0.0 | -3.5 | -0.3 | 0.3 |
Income Before Income Taxes | -2.1 | -8.2 | -14.6 | -12.3 | -16.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -2.1 | -8.2 | -14.6 | -12.3 | -16.2 |
Consolidated Net Income / Loss | -2.1 | -8.2 | -14.6 | -12.3 | -16.2 |
Net Income Attributable to Common Shareholders | -2.1 | -8.2 | -14.6 | -12.3 | -16.2 |
Basic EPS | -$3.50 | -$14.58 | -$11.04 | -$8.94 | -$6.68 |
Diluted EPS | -$3.50 | -$14.58 | -$11.04 | -$8.94 | -$6.68 |
Basic Shares Outstanding | 0.6M | 0.6M | 1.3M | 1.4M | 2.4M |
Diluted Shares Outstanding | 0.6M | 0.6M | 1.3M | 1.4M | 2.4M |